[Clinical experience with oxendolone for treatment of benign prostatic hyperplasia. Clinical efficacy and effects on serum lipid and lipoprotein fraction levels].

Abstract

Forty-three patients with benign prostatic hyperplasia were treated with weekly i.m. injections of 400 mg oxendolone for 12 weeks. The subjective symptoms were improved in 83% of these patients. Residual urine was decreased significantly and Qmax was increased by this treatment. Serum VLDL level was suppressed significantly, whereas the levels of LDL, total cholesterol, HDL-cholesterol and triglycerides were changed little. Atherosclerotic index and the ratio of (total cholesterol--HDL-cholesterol) to (HDL-cholesterol), was not influenced by the treatment. No severe side-effect was found. These findings suggest that oxendolone is the drug of choice for non-surgical treatment of benign prostatic hyperplasia.

• Authors: A Yasukawa, H Nihira, S Matsuki, M Fujii, H Fujiwara, T Kitano, M Kodama, R Ukai, O Tado, K Sagami
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 30 Issue 4 Pg. 537-43 (Apr 1984) ISSN: 0018-1994 [Print] Japan
• PMID: 6207714 (Publication Type: English Abstract, Journal Article)

Chemical References

• Androgen Antagonists
• Lipids
• Lipoproteins
• Nandrolone
• oxendolone

Topics

• Aged
• Androgen Antagonists (therapeutic use)
• Drug Evaluation
• Humans
• Lipids (blood)
• Lipoproteins (blood)
• Male
• Middle Aged
• Nandrolone (analogs & derivatives, therapeutic use)
• Prostatic Hyperplasia (blood, drug therapy)